Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1636651/000156459018025039/ovid-8k_20181025.htm
November 2022
August 2022
June 2022
May 2022
May 2022
March 2022
January 2022
November 2021
October 2021
August 2021
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1636651/000156459018025039/ovid-8k_20181025.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Ovid Therapeutics Inc..
Ovid Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Ovid Therapeutics Inc. provided additional information to their SEC Filing as exhibits
Ticker: OVIDEvents:
CIK: 1636651
Form Type: 8-K Corporate News
Accession Number: 0001564590-18-025039
Submitted to the SEC: Thu Oct 25 2018 10:25:40 AM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Thursday, October 25, 2018
Industry: Pharmaceutical Preparations